Public Meeting


  • When: September 14, 2017
  • Where: Phenomenex Headquarters
                     411 Madrid Ave, Torrance, CA
  • Time:  6 to 9 PM
  • A light dinner will be served at 6:00 PM, courtesy of Phenomenex, Inc.
  • Dr. Joseph Loo and Dr. Jeff Raber will present their research  

Due to overwhelming response to attend our first meeting, the conference hall facility has reached its maximum occupancy. The registration is now closed. We thank you for your patience and understanding.


A word about the presenters


Joseph A. Loo, Ph.D.
Department of Chemistry and Biochemistry
Department of Biological Chemistry, David Geffen School of Medicine
University of California-Los Angeles, Los Angeles, CA


Bio
Joseph A. Loo is a Professor in the Department of Biological Chemistry, David Geffen School of Medicine, and in the Department of Chemistry & Biochemistry at the University of California, Los Angeles (UCLA). He is also a member of UCLA/DOE Institute for Genomics and Proteomics and the UCLA Molecular Biology Institute. His research interests include analytical chemistry, the mass spectrometry characterization of peptides and proteins and post-translational modifications, and their application for proteomics and disease biomarkers. He is the author of over 280 scientific publications. He is on the Editorial Boards of several scientific journals, and currently he is the Editor-in-Chief for the Journal of the American Society for Mass Spectrometry. He has held leadership and advisory positions with scientific organizations, including membership on the Board of Directors for the American Society for Mass Spectrometry (ASMS) and the US Human Proteome Organization (US HUPO). Before he joined UCLA in 2001, he was an Associate Research Fellow and Group Leader of the Biological Mass Spectrometry and Proteomics Teams at Parke-Davis Pharmaceutical (currently Pfizer Global Research), Ann Arbor, MI. Dr. Loo received his Ph.D. in analytical chemistry from Cornell University with Professor Fred W. McLafferty, where he worked on the development of high resolution mass spectrometry for bioanalytical applications. He carried out research as a post-doctoral fellow, and later as a Senior Scientist, at Pacific Northwest National Laboratory (Richland, WA) with Dr. Richard Smith on the development of electrospray ionization mass spectrometry and capillary electrophoresis for protein characterization.



Abstract


Application of Mass Spectrometry for Detecting and Finding Cures to Brain Disorders
Bioanalytical mass spectrometry can play important roles to positively impact our ability to detect human health disorders and to develop potential therapies. Our laboratory has been engaged in research to determine the mechanistic basis of compounds that inhibit protein aggregation found in neurodegenerative disorders, such as Alzheimer’s and Parkinson’s diseases. Protein mass spectrometry and tandem mass spectrometry are key techniques used in these studies. The role of mass spectrometry and quantitative liquid chromatography/MS in our work to discover new protein biomarkers for head trauma, or traumatic brain injury will also be highlighted in this presentation.




 *******************************************************************************************************************************



Jeffrey C. Raber, Ph.D.
CEO
The Werc Shop
​Monrovia, CA 91016
www.TheWercShop.com
310-703-9567

Bio

Dr. Raber received his B.S. in biochemistry from Lebanon Valley College, PA and subsequently a Ph.D. in organic chemistry from the University of Southern California with an emphasis on developing new synthetic methodologies useful in pharmaceutical drug discovery and manufacturing efforts. Dr. Raber studied botanical phylogenetic relationships based on the RuBisCO enzyme’s evolution while in college and was named to the USA Today 1997 All-USA College Academic Team for his research accomplishments in this area. While at USC he was awarded the Harold and Lillian Moulton Fellowship for his efforts on the construction of novel heterocycles and peptidomimetics utilizing a proprietary boron-based multicomponent condensation reaction. Driven by a desire to find his own medicine and make a positive contribution to society while creating American jobs, Dr. Raber founded The Werc Shop in 2010 with a focus on botanical analysis, new product developments and sustainability. The Werc Shop’s first goal was addressing unmet public health and safety needs within the medical cannabis community. Dr. Raber’s detailed investigations into the chemistry of cannabis, including 5 peer reviewed publications to date, provide him with a unique perspective and knowledge base useful in assisting state and local regulators in the construction and implementation of effective regulatory solutions for the safe and sustainable delivery of medical cannabis to qualified patients and adult consumers. His technical insights and understanding of the complex regulatory scope continue to prove very helpful in assisting many entrepreneurs in their efforts within the cannabis arena.



 Abstract


Advancing Whole-Plant Cannabis Understanding
Cannabis sativa L. is an exceptionally diverse plant rapidly rising in acceptance as a physiologically useful tool for alleviating numerous chronic ailments. The use of whole-plant cannabis products often offers greater therapeutic effectiveness than single molecule cannabinoid approaches. This presents unique challenges in determining product chemical compositions required for entering the clinic. Furthermore, metabolic profiling of these compositions can be exceptionally complex and require the development of advanced analytical methodologies to provide useful clinical insight. Currently new laws and regulations around cannabis are being established for California which will require mandatory testing to be performed all along the supply chain for both medical and adult use products. An overview of product types and testing methods will be presented.